ARS Pharmaceuticals, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

ARS Pharmaceuticals, Inc. reported Cash And Cash Equivalents At Carrying Value of $41.32 million for the year ending 2025.

  • ARS Pharmaceuticals, Inc. showed a decrease of -18.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from ARS Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
  • XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 6 years of available data (2020 to 2025), ARS Pharmaceuticals, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 89.3%.
  • Historical annual values: Fiscal year 2025: $41.32 million | Fiscal year 2024: $50.82 million | Fiscal year 2023: $70.97 million | Fiscal year 2022: $210.52 million | Fiscal year 2021: $60.06 million | Fiscal year 2020: $386.57 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: